C. Picard‐Dahan

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 596 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control Study

Sylvie Bastuji‐Garin, P. Joly, Pauline Lemordant et al. · Journal of Investigative Dermatology · 2010 · 299 citations · Full text

Medicine, Geriatric Medicine, Health Sciences +7

Risk Factors for Relapse in Patients With Bullous Pemphigoid in Clinical Remission

Philippe Bernard, Z. Reguiaï, Emmanuelle Tancrède‐Bohin et al. · Archives of Dermatology · 2009 · 110 citations

Life Sciences, Dermatology, Immunology +17

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

D.M. Chen, Adefowope Odueyungbo, Eva Csinady et al. · British Journal of Dermatology · 2019 · 95 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score ( <scp>ABSIS</scp> ) and Pemphigus Disease Area Index ( <scp>PDAI</scp> ) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus

C. Boulard, S. Duvert Lehembre, C. Picard‐Dahan et al. · British Journal of Dermatology · 2016 · 92 citations · Full text

Medicine, Dermatology, Autoimmunity +16